<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinicaloncology</journal-id><journal-title-group><journal-title xml:lang="ru">Клинический случай в онкологии</journal-title><trans-title-group xml:lang="en"><trans-title>Clinical Case in Oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-1477</issn><publisher><publisher-name>ОНКОПРАКТИК</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.62546/3034-1477-2025-3-3-7-13</article-id><article-id custom-type="elpub" pub-id-type="custom">clinicaloncology-132</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group></article-categories><title-group><article-title>Профиль токсичности ингибиторов циклин-зависимых киназ в условиях реальной клинической практики</article-title><trans-title-group xml:lang="en"><trans-title>Modern international guidelines for the management of patients after completion of breast cancer treatment: an evidencebased review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4447-9458</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орлова</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Orlova</surname><given-names>Rashida V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>199106, Санкт-Петербург, 21-я линия В.О., д. 8а</p><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p></bio><bio xml:lang="en"><p>7/9 Universitetskaya Emb., St. Petersburg, 199034</p><p>56 Veteranov Ave., St. Petersburg, 193318</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7111-1507</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андросова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Androsova</surname><given-names>Aleksandra V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андросова Александра Валерьевна </p><p>199106, Санкт-Петербург, 21-я линия В.О., д. 8а</p><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p></bio><bio xml:lang="en"><p>7/9 Universitetskaya Emb., St. Petersburg, 199034</p><p>56 Veteranov Ave., St. Petersburg, 193318</p></bio><email xlink:type="simple">alexa.androsova.1711@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2003-7938</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авраменко</surname><given-names>И.</given-names></name><name name-style="western" xml:lang="en"><surname>Avramenko</surname><given-names>Inna V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p></bio><bio xml:lang="en"><p>56 Veteranov Ave., St. Petersburg, 193318</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1700-1128</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Топузов</surname><given-names>Э. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Topuzov</surname><given-names>Eldar E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p><p>191015, Санкт-Петербург, Кирочная ул., д. 41 </p></bio><bio xml:lang="en"><p>56 Veteranov Ave., St. Petersburg, 193318</p><p>41, Kirochnaya Street, St. Petersburg, 191015</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0402-6067</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беляк</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyak</surname><given-names>Natalia P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>199106, Санкт-Петербург, 21-я линия В.О., д. 8а</p><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p></bio><bio xml:lang="en"><p>7/9 Universitetskaya Emb., St. Petersburg, 199034</p><p>56 Veteranov Ave., St. Petersburg, 193318</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2221-4088</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутукова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutukova</surname><given-names>Svetlana I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8</p></bio><bio xml:lang="en"><p>6–8 L. Tolstoy Str., St. Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Варанкина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Varankina</surname><given-names>Anna A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p></bio><bio xml:lang="en"><p>56 Veteranov Ave., St. Petersburg, 193318</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1321-3657</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вахитова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vakhitova</surname><given-names>Almira A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p></bio><bio xml:lang="en"><p>56 Veteranov Ave., St. Petersburg, 193318</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8965-8364</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глузман</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gluzman</surname><given-names>Mark I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>199106, Санкт-Петербург, 21-я линия В.О., д. 8а</p><p>198255, Санкт-Петербург, пр. Ветеранов, д. 56 </p></bio><bio xml:lang="en"><p>7/9 Universitetskaya Emb., St. Petersburg, 199034</p><p>56 Veteranov Ave., St. Petersburg, 193318</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный университет»; СПб ГБУЗ «Городской клинический онкологический диспансер»<country>Россия</country></aff><aff xml:lang="en">St. Petersburg State University; St. Petersburg City Clinical Oncology Dispensary<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">СПб ГБУЗ «Городской клинический онкологический диспансер»<country>Россия</country></aff><aff xml:lang="en">St. Petersburg State University; St. Petersburg City Clinical Oncology Dispensary<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">СПб ГБУЗ «Городской клинический онкологический диспансер»; ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России<country>Россия</country></aff><aff xml:lang="en">St. Petersburg City Clinical Oncology Dispensary; North-Western State Medical University named after I.I.Mechnikov<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Pavlov First St. Petersburg State Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru">СПб ГБУЗ «Городской клинический онкологический диспансер»<country>Россия</country></aff><aff xml:lang="en">St. Petersburg City Clinical Oncology Dispensary<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>01</month><year>2026</year></pub-date><volume>3</volume><issue>3</issue><fpage>7</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Орлова Р.В., Андросова А.В., Авраменко И.V., Топузов Э.Э., Беляк Н.П., Кутукова С.И., Варанкина А.А., Вахитова А.А., Глузман М.И., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Орлова Р.В., Андросова А.В., Авраменко И., Топузов Э.Э., Беляк Н.П., Кутукова С.И., Варанкина А.А., Вахитова А.А., Глузман М.И.</copyright-holder><copyright-holder xml:lang="en">Orlova R.V., Androsova A.V., Avramenko I.V., Topuzov E.E., Belyak N.P., Kutukova S.I., Varankina A.A., Vakhitova A.A., Gluzman M.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncocase.ru/jour/article/view/132">https://www.oncocase.ru/jour/article/view/132</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Успехи в лечении рака молочной железы (РМЖ) привели к формированию многочисленной и постоянно растущей популяции пациенток, перенесших заболевание. Это обусловливает сдвиг клинической парадигмы от фокуса исключительно на выживаемости к комплексному управлению долгосрочным здоровьем и качеством жизни.</p></sec><sec><title>Цель</title><p>Цель. Провести критический анализ и синтез современных доказательных данных по ключевым аспектам ведения пациенток после РМЖ, акцентируя внимание на переходе от пассивного наблюдения к проактивным стратегиям реабилитации и вторичной профилактики.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен систематизированный анализ данных из ключевых рандомизированных клинических исследований (РКИ), метаанализов (Cochrane, EBCTCG) и клинических рекомендаций (ESMO, NCCN). Проанализирована эффективность протоколов наблюдения, влияние факторов образа жизни, методы управления осложнениями эндокринной терапии и современные подходы к сохранению репродуктивной функции.</p></sec><sec><title>Результаты</title><p>Результаты. Анализ демонстрирует научный консенсус в отношении нецелесообразности интенсивного инструментального скрининга у бессимптомных пациенток. Напротив, убедительно доказана роль модификации образа жизни, где контроль массы тела и регулярная физическая активность являются ключевыми факторами снижения риска рецидива и смертности. Управление долгосрочными осложнениями эндокринотерапии, такими как остеопороз и генитоуринарный синдром, требует проактивного подхода, включающего применение костно-модифицирующих агентов (обладающих также противоопухолевым эффектом) и безопасных методов локальной гормональной коррекции. Прорывом в репродуктивной онкологии стало исследование POSITIVE, доказавшее безопасность временного прерывания терапии для реализации материнства, что кардинально меняет подходы к консультированию молодых пациенток.</p></sec><sec><title>Заключение</title><p>Заключение. Современная концепция ведения пациенток после РМЖ требует перехода к персонализированным планам выживаемости (survivorship care plans). Эти планы должны интегрировать доказательные стратегии наблюдения, проактивное управление побочными эффектами, обязательный скрининг и коррекцию психологического дистресса, а также активное вовлечение пациенток в модификацию образа жизни. Дальнейшие исследования должны быть направлены на разработку эффективных моделей внедрения этих комплексных подходов в рутинную клиническую практику. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Advances in breast cancer (BC) treatment have led to a large and growing population of survivors. This necessitates a clinical paradigm shift from a sole focus on survival to the comprehensive management of long-term health and quality of life.</p></sec><sec><title>Objective</title><p>Objective. To critically analyze and synthesize current evidence-based data on key aspects of post-treatment BC care, emphasizing the transition from passive surveillance to proactive strategies for rehabilitation and secondary prevention.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A systematic analysis of data from key randomized clinical trials (RCTs), meta-analyses (Cochrane, EBCTCG), and clinical guidelines (ESMO, NCCN) was conducted. The review covers the efficacy of follow-up protocols, the impact of lifestyle factors, methods for managing endocrine therapy complications, and modern approaches to fertility preservation.</p></sec><sec><title>Results</title><p>Results. The analysis reveals a scientific consensus on the inefficacy of intensive instrumental screening in asymptomatic patients. Conversely, the role of lifestyle modification is strongly evidenced, with body weight control and regular physical activity being key factors in reducing the risk of recurrence and mortality. Managing long-term complications of endocrine therapy, such as osteoporosis and genitourinary syndrome, requires a proactive approach, including the use of bone-modifying agents (which also possess antitumor effects) and safe methods of local hormonal treatment. The POSITIVE trial represents a breakthrough in oncofertility, proving the safety of temporarily interrupting therapy to pursue pregnancy, which fundamentally changes counseling for young patients.</p></sec><sec><title>Conclusion</title><p>Conclusion. The modern concept of BC survivorship care demands a shift towards personalized survivorship care plans. These plans must integrate evidence-based surveillance strategies, proactive management of side effects, mandatory screening and correction of psychological distress, and active patient engagement in lifestyle modification. Future research should focus on developing effective models for implementing these comprehensive approaches into routine clinical practice.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>выживаемость</kwd><kwd>качество жизни</kwd><kwd>план выживаемости</kwd><kwd>проактивное ведение</kwd><kwd>вторичная профилактика</kwd><kwd>реабилитация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>survivorship</kwd><kwd>quality of life</kwd><kwd>survivorship care plan</kwd><kwd>proactive management</kwd><kwd>secondary prevention</kwd><kwd>rehabilitation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // CA Cancer J. Clin. 2021. Vol. 71, No. 3. Р. 209–249.</mixed-citation><mixed-citation xml:lang="en">Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // CA Cancer J. Clin. 2021. Vol. 71, No. 3. Р. 209–249.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">ESMO Patient Guide: Breast Cancer Survivorship. [Электронный ресурс]. URL: https://www.esmo.org/content/download/193218/3522776/1/EN-Breast-Cancer-Survivorship-Guide-forPatients.pdf (дата обращения: 20.10.2023).</mixed-citation><mixed-citation xml:lang="en">ESMO Patient Guide: Breast Cancer Survivorship. [Электронный ресурс]. URL: https://www.esmo.org/content/download/193218/3522776/1/EN-Breast-Cancer-Survivorship-Guide-forPatients.pdf (дата обращения: 20.10.2023).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mocchetti I., Nanni O., De Censi A. Follow-up strategies for women treated for early breast cancer // Cochrane Database of Systematic Reviews. 2015, No. 2. CD001768.</mixed-citation><mixed-citation xml:lang="en">Mocchetti I., Nanni O., De Censi A. Follow-up strategies for women treated for early breast cancer // Cochrane Database of Systematic Reviews. 2015, No. 2. CD001768.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Moscetti L., Nasso C., Piacentini F. et al. How breast cancer recurrences are detected: a retrospective analysis of 20,650 follow-up visits // J. Clin. Oncol. 2023. Vol. 41, No. 16, suppl. e12520.</mixed-citation><mixed-citation xml:lang="en">Moscetti L., Nasso C., Piacentini F. et al. How breast cancer recurrences are detected: a retrospective analysis of 20,650 follow-up visits // J. Clin. Oncol. 2023. Vol. 41, No. 16, suppl. e12520.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lahart I.M., Metsios G.S., Nevill A.M., Carmichael A.R. Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies // Acta Oncol. 2015. Vol. 54, No. 5. Р. 635–654.</mixed-citation><mixed-citation xml:lang="en">Lahart I.M., Metsios G.S., Nevill A.M., Carmichael A.R. Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies // Acta Oncol. 2015. Vol. 54, No. 5. Р. 635–654.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Holmes M.D., Chen W.Y., Feskanich D., Kroenke C.H., Colditz G.A. Physical activity and survival after breast cancer diagnosis // JAMA. 2005. Vol. 293, No. 20. Р. 2479–2486.</mixed-citation><mixed-citation xml:lang="en">Holmes M.D., Chen W.Y., Feskanich D., Kroenke C.H., Colditz G.A. Physical activity and survival after breast cancer diagnosis // JAMA. 2005. Vol. 293, No. 20. Р. 2479–2486.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis // JAMA Oncol. 2017;3, No. 7. Р. 961–968.</mixed-citation><mixed-citation xml:lang="en">Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis // JAMA Oncol. 2017;3, No. 7. Р. 961–968.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Irwin M.L., Cartmel B., Gross C. et al. Randomized controlled trial of exercise on aromatase inhibitor-associated arthralgias in women with breast cancer // J. Clin. Oncol. 2015. Vol. 33, No. 10. Р. 1104–1111.</mixed-citation><mixed-citation xml:lang="en">Irwin M.L., Cartmel B., Gross C. et al. Randomized controlled trial of exercise on aromatase inhibitor-associated arthralgias in women with breast cancer // J. Clin. Oncol. 2015. Vol. 33, No. 10. Р. 1104–1111.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chlebowski R.T., Aragaki A.K., Anderson G.L. et al. Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women’s Health Initiative Randomized Controlled Trial // J. Clin. Oncol. 2017. Vol. 35, No. 25. Р. 2919–2926.</mixed-citation><mixed-citation xml:lang="en">Chlebowski R.T., Aragaki A.K., Anderson G.L. et al. Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women’s Health Initiative Randomized Controlled Trial // J. Clin. Oncol. 2017. Vol. 35, No. 25. Р. 2919–2926.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pierce J.P., Natarajan L., Caan B.J. et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial // JAMA. 2007. Vol. 298, No. 3. Р. 289–298.</mixed-citation><mixed-citation xml:lang="en">Pierce J.P., Natarajan L., Caan B.J. et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial // JAMA. 2007. Vol. 298, No. 3. Р. 289–298.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chan D.S.M., Vieira A.R., Aune D. et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies // Ann. Oncol. 2014. Vol. 25, No. 10. Р. 1901–1914.</mixed-citation><mixed-citation xml:lang="en">Chan D.S.M., Vieira A.R., Aune D. et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies // Ann. Oncol. 2014. Vol. 25, No. 10. Р. 1901–1914.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Survivorship. Version 1.2023.</mixed-citation><mixed-citation xml:lang="en">NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Survivorship. Version 1.2023.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Butow P., Turner J., Gilchrist J. et al. ConquerFear: a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence // J. Clin. Oncol. 2017. Vol. 35, No. 32. Р. 3680–3688.</mixed-citation><mixed-citation xml:lang="en">Butow P., Turner J., Gilchrist J. et al. ConquerFear: a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence // J. Clin. Oncol. 2017. Vol. 35, No. 32. Р. 3680–3688.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hummel S.B., van Lankveld J.J., Oldenburg H.S. et al. Internet-Based Cognitive Behavioral Therapy for Sexual Dysfunctions in Women Treated for Breast Cancer: A Randomized Controlled Trial // J. Clin. Oncol. 2017. Vol. 35, No. 7. Р. 757–765.</mixed-citation><mixed-citation xml:lang="en">Hummel S.B., van Lankveld J.J., Oldenburg H.S. et al. Internet-Based Cognitive Behavioral Therapy for Sexual Dysfunctions in Women Treated for Breast Cancer: A Randomized Controlled Trial // J. Clin. Oncol. 2017. Vol. 35, No. 7. Р. 757–765.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffman C.J., Ersser S.J., Hopkinson J.B. et al. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial // J. Clin. Oncol. 2012. Vol. 30, No. 12. Р. 1335–1342.</mixed-citation><mixed-citation xml:lang="en">Hoffman C.J., Ersser S.J., Hopkinson J.B. et al. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial // J. Clin. Oncol. 2012. Vol. 30, No. 12. Р. 1335–1342.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hershman D.L., Kushi L.H., Hillyer D. et al. Adherence to adjuvant tamoxifen and survival in women with breast cancer // J. Clin. Oncol. 2011. Vol. 29, No. 15, suppl. Р. 6023.</mixed-citation><mixed-citation xml:lang="en">Hershman D.L., Kushi L.H., Hillyer D. et al. Adherence to adjuvant tamoxifen and survival in women with breast cancer // J. Clin. Oncol. 2011. Vol. 29, No. 15, suppl. Р. 6023.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gnant M., Pfeiler G., Dubsky P.C. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial // Lancet. 2015. Vol. 386, No. 9992. Р. 433–443.</mixed-citation><mixed-citation xml:lang="en">Gnant M., Pfeiler G., Dubsky P.C. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial // Lancet. 2015. Vol. 386, No. 9992. Р. 433–443.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson C., Bell R., Hinsley S. et al. Adjuvant zoledronic acid reduces fractures in adults with early-stage breast cancer: a systematic review and meta-analysis of randomised controlled trials // Breast Cancer Res. 2018. Vol. 20, No. 1. Р. 143.</mixed-citation><mixed-citation xml:lang="en">Wilson C., Bell R., Hinsley S. et al. Adjuvant zoledronic acid reduces fractures in adults with early-stage breast cancer: a systematic review and meta-analysis of randomised controlled trials // Breast Cancer Res. 2018. Vol. 20, No. 1. Р. 143.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials // Lancet. 2015. Vol. 386, No. 10001. Р. 1353–1361.</mixed-citation><mixed-citation xml:lang="en">Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials // Lancet. 2015. Vol. 386, No. 10001. Р. 1353–1361.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Coleman R., Finkelstein D.M., Bundred N. et al. D-CARE: A phase III, randomized, double-blind, placebo-controlled trial of denosumab to prevent bone metastases in women with high-risk early breast cancer // J. Clin. Oncol. 2020. Vol. 38, No. 18, suppl. Р. 501.</mixed-citation><mixed-citation xml:lang="en">Coleman R., Finkelstein D.M., Bundred N. et al. D-CARE: A phase III, randomized, double-blind, placebo-controlled trial of denosumab to prevent bone metastases in women with high-risk early breast cancer // J. Clin. Oncol. 2020. Vol. 38, No. 18, suppl. Р. 501.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Franzoi M.A., Agostinetto E., Perachino M. et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer // Lancet Oncol. 2021. Vol. 22, No. 7. Р. e303-e313.</mixed-citation><mixed-citation xml:lang="en">Franzoi M.A., Agostinetto E., Perachino M. et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer // Lancet Oncol. 2021. Vol. 22, No. 7. Р. e303-e313.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Le Ray I., Dell’aniello S., Bonnetain F., Azoulay L., Suissa S. Local estrogen therapy and risk of breast cancer recurrence among patients receiving aromatase inhibitors: a cohort study // Breast Cancer Res. Treat. 2012. Vol. 135, No. 2. Р. 655–661.</mixed-citation><mixed-citation xml:lang="en">Le Ray I., Dell’aniello S., Bonnetain F., Azoulay L., Suissa S. Local estrogen therapy and risk of breast cancer recurrence among patients receiving aromatase inhibitors: a cohort study // Breast Cancer Res. Treat. 2012. Vol. 135, No. 2. Р. 655–661.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lambertini M., Moore H.C.F., Leonard R.C.F. et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data // J. Clin. Oncol. 2018. Vol. 36, No. 19. Р. 1981–1990.</mixed-citation><mixed-citation xml:lang="en">Lambertini M., Moore H.C.F., Leonard R.C.F. et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data // J. Clin. Oncol. 2018. Vol. 36, No. 19. Р. 1981–1990.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lambertini M., Kroman N., Ameye L. et al. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis // J. Clin. Oncol. 2017. Vol. 35, No. 30. Р. 3453–3465.</mixed-citation><mixed-citation xml:lang="en">Lambertini M., Kroman N., Ameye L. et al. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis // J. Clin. Oncol. 2017. Vol. 35, No. 30. Р. 3453–3465.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Partridge A.H., Niman S.M., Ruggeri M. et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer // N. Engl. J. Med. 2023. Vol. 388, No. 18. Р. 1645–1656.</mixed-citation><mixed-citation xml:lang="en">Partridge A.H., Niman S.M., Ruggeri M. et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer // N. Engl. J. Med. 2023. Vol. 388, No. 18. Р. 1645–1656.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
